RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.
Recent advances in RNA delivery and target selection provide unprecedented opportunities for cancer treatment, especially for cancers that are particularly hard to treat with existing drugs. Small interfering RNAs, microRNAs, and antisense oligonucleotides are the most widely used strategies for silencing gene expression. In this review, we summarize how these approaches were used to develop drugs targeting RNA in human cells. Then, we review the current state of clinical trials of these agents for different types of cancer and outcomes from published data. Finally, we discuss lessons learned from completed studies and future directions for this class of drugs.
Department of Solid Tumors, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA.
Pedro
P
Barata
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anil K
AK
Sood
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: dshong@mdanderson.org.
David S
DS
Hong
D002986:Clinical Trials as Topic; D006801:Humans; D035683:MicroRNAs / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use*; D034741:RNA, Small Interfering / Q000627:therapeutic use*; D000067492:RNAi Therapeutics / Q000379:methods*
D035683:MicroRNAs; D016376:Oligonucleotides, Antisense; D034741:RNA, Small Interfering
Antisense oligonucleotides; Cancer clinical trials; RNA therapeutics; miRNA; siRNA